vs

Side-by-side financial comparison of Bioceres Crop Solutions Corp. (BIOX) and Ouster, Inc. (OUST). Click either name above to swap in a different company.

Bioceres Crop Solutions Corp. is the larger business by last-quarter revenue ($77.6M vs $62.2M, roughly 1.2× Ouster, Inc.). On growth, Ouster, Inc. posted the faster year-over-year revenue change (106.6% vs -16.8%). Over the past eight quarters, Ouster, Inc.'s revenue compounded faster (54.8% CAGR vs -8.4%).

Bioceres Crop Solutions Corp is a global agricultural technology firm that develops and commercializes sustainable crop solutions including drought-tolerant seed traits, biofertilizers, and biopesticides. It serves farmers across South America, North America, Europe and Asia-Pacific, focusing on raising crop yields while reducing the environmental footprint of agricultural activities.

Ouster, Inc. is an American lidar technology company headquartered in San Francisco, California. It builds high-resolution, digital 3D lidar sensors for use in autonomous vehicles, industrial, robotics, drones, mapping, defense, and security systems.

BIOX vs OUST — Head-to-Head

Bigger by revenue
BIOX
BIOX
1.2× larger
BIOX
$77.6M
$62.2M
OUST
Growing faster (revenue YoY)
OUST
OUST
+123.4% gap
OUST
106.6%
-16.8%
BIOX
Faster 2-yr revenue CAGR
OUST
OUST
Annualised
OUST
54.8%
-8.4%
BIOX

Income Statement — Q1 FY2026 vs Q4 FY2025

Metric
BIOX
BIOX
OUST
OUST
Revenue
$77.6M
$62.2M
Net Profit
$-7.4M
Gross Margin
46.8%
60.2%
Operating Margin
9.3%
1.5%
Net Margin
-9.6%
Revenue YoY
-16.8%
106.6%
Net Profit YoY
-20.2%
EPS (diluted)
$-0.12
$0.10

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
BIOX
BIOX
OUST
OUST
Q4 25
$62.2M
Q3 25
$77.6M
$39.5M
Q2 25
$35.0M
Q1 25
$60.6M
$32.6M
Q4 24
$98.8M
$30.1M
Q3 24
$93.3M
$28.1M
Q2 24
$27.0M
Q1 24
$84.0M
$25.9M
Net Profit
BIOX
BIOX
OUST
OUST
Q4 25
Q3 25
$-7.4M
$-21.7M
Q2 25
$-20.6M
Q1 25
$-1.6M
$-22.0M
Q4 24
$605.2K
Q3 24
$-6.2M
$-25.6M
Q2 24
$-23.9M
Q1 24
$9.8M
$-23.8M
Gross Margin
BIOX
BIOX
OUST
OUST
Q4 25
60.2%
Q3 25
46.8%
42.1%
Q2 25
45.2%
Q1 25
39.4%
41.3%
Q4 24
42.0%
43.8%
Q3 24
40.2%
38.3%
Q2 24
33.7%
Q1 24
50.8%
28.6%
Operating Margin
BIOX
BIOX
OUST
OUST
Q4 25
1.5%
Q3 25
9.3%
-61.4%
Q2 25
-76.5%
Q1 25
1.5%
-73.0%
Q4 24
14.5%
-85.1%
Q3 24
2.5%
-98.0%
Q2 24
-93.6%
Q1 24
15.7%
-99.5%
Net Margin
BIOX
BIOX
OUST
OUST
Q4 25
Q3 25
-9.6%
-55.0%
Q2 25
-58.8%
Q1 25
-2.6%
-67.5%
Q4 24
0.6%
Q3 24
-6.6%
-91.1%
Q2 24
-88.4%
Q1 24
11.6%
-91.9%
EPS (diluted)
BIOX
BIOX
OUST
OUST
Q4 25
$0.10
Q3 25
$-0.12
$-0.37
Q2 25
$-0.38
Q1 25
$-0.02
$-0.42
Q4 24
$0.00
$-0.46
Q3 24
$-0.10
$-0.54
Q2 24
$-0.53
Q1 24
$0.14
$-0.55

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
BIOX
BIOX
OUST
OUST
Cash + ST InvestmentsLiquidity on hand
$15.5M
$208.6M
Total DebtLower is stronger
Stockholders' EquityBook value
$288.3M
$261.7M
Total Assets
$734.9M
$349.5M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
BIOX
BIOX
OUST
OUST
Q4 25
$208.6M
Q3 25
$15.5M
$244.5M
Q2 25
$226.5M
Q1 25
$38.5M
$168.2M
Q4 24
$29.2M
$172.0M
Q3 24
$32.3M
$151.4M
Q2 24
$184.2M
Q1 24
$16.4M
$187.8M
Stockholders' Equity
BIOX
BIOX
OUST
OUST
Q4 25
$261.7M
Q3 25
$288.3M
$247.4M
Q2 25
$221.0M
Q1 25
$345.0M
$167.9M
Q4 24
$346.3M
$180.9M
Q3 24
$346.0M
$171.7M
Q2 24
$170.6M
Q1 24
$348.5M
$167.2M
Total Assets
BIOX
BIOX
OUST
OUST
Q4 25
$349.5M
Q3 25
$734.9M
$353.8M
Q2 25
$321.8M
Q1 25
$798.2M
$268.6M
Q4 24
$835.2M
$276.1M
Q3 24
$827.3M
$255.2M
Q2 24
$309.9M
Q1 24
$836.1M
$317.7M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
BIOX
BIOX
OUST
OUST
Operating Cash FlowLast quarter
$14.4M
$-15.4M
Free Cash FlowOCF − Capex
$-37.2M
FCF MarginFCF / Revenue
-59.8%
Capex IntensityCapex / Revenue
35.0%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-64.8M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
BIOX
BIOX
OUST
OUST
Q4 25
$-15.4M
Q3 25
$14.4M
$-18.3M
Q2 25
$-1.3M
Q1 25
$23.3M
$-4.9M
Q4 24
$-5.4M
$-2.6M
Q3 24
$5.2M
$-3.8M
Q2 24
$-21.6M
Q1 24
$-17.4M
$-5.7M
Free Cash Flow
BIOX
BIOX
OUST
OUST
Q4 25
$-37.2M
Q3 25
$-20.0M
Q2 25
$-2.2M
Q1 25
$-5.4M
Q4 24
$-4.0M
Q3 24
$-4.3M
Q2 24
$-22.0M
Q1 24
$-7.1M
FCF Margin
BIOX
BIOX
OUST
OUST
Q4 25
-59.8%
Q3 25
-50.7%
Q2 25
-6.3%
Q1 25
-16.6%
Q4 24
-13.3%
Q3 24
-15.4%
Q2 24
-81.5%
Q1 24
-27.4%
Capex Intensity
BIOX
BIOX
OUST
OUST
Q4 25
35.0%
Q3 25
4.3%
Q2 25
2.5%
Q1 25
1.7%
Q4 24
4.8%
Q3 24
2.0%
Q2 24
1.3%
Q1 24
5.3%
Cash Conversion
BIOX
BIOX
OUST
OUST
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
-8.85×
Q3 24
Q2 24
Q1 24
-1.78×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons